Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455819 | 0.88 | PDE4B (0.59) | PDE4BPDE4DFLT3ALDH1A1MEN1 | |
| SCHEMBL5451626 | 0.87 | PDE4B (0.55) | PDE4BPDE4DFLT3MEN1KMT2A | |
| SCHEMBL5460149 | 0.85 | PDE4B (0.49) | PDE4BPDE4DSMN1; SMN2MEN1GAA | |
| SCHEMBL5450630 | 0.83 | MAPT (0.46) | PDE4BPDE4DFLT3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5452256 | 0.80 | TLR2 (0.53) | FLT3ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL5444976 | 0.80 | MEN1 (0.51) | PDE4BPDE4DMEN1GAAKMT2A | |
| SCHEMBL5452205 | 0.79 | MEN1 (0.52) | PDE4BFLT3SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5454151 | 0.79 | FLT3 (0.53) | FLT3SMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL5453162 | 0.79 | KCNH2 (0.48) | PDE4BPDE4DMEN1KMT2ACCR6 | |
| SCHEMBL5467285 | 0.78 | FLT3 (0.53) | FLT3SMN1; SMN2ALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | PDE4B 1387/4885PDE4D 1518/4885FLT3 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.